Semaglutide Pills and its Impact on Cardiovascular Health

Table of Contents

Introduction:

Semaglutide pill is a new arrival in the field of medicine. These pills are used to treat Type 2 Diabetes in adults. It inhibit the secretion of glucagon and increases the secretion of insulin in your body. It activates the brain receptors that releases the hormone named Glucagon Like Peptide-1 (GLP-1). This will slow down the digestion of food and you feel stiated. This feeling of fullness forces you to eat less which helps you in weight management.

Dosage:

Semaglutide pills are taken once daily.It is available in strength of 3mg, 7mg and 14mg.
The strength is increased after 30 days in a condition if blood sugar level is not controlled with low potency.
Semaglutide pills are ingested 30 minute before meal with plain water.
Do not use cold drinks or beverages for taking medicine.
Do not break or chew the pill.

Impact on Cardiovascular Health:

Semaglutide pills have shown a positive impact on cardiovascular health, particularly in individuals with type 2 diabetes. Clinical trials and studies have revealed that semaglutide not only helps in managing blood sugar levels and weight but also reduces the risk of cardiovascular events. This includes a decreased risk of heart attacks and strokes in diabetic patients.

Semaglutide belongs to the class of GLP-1 receptor agonists, which have demonstrated cardiovascular benefits. While the exact mechanisms are not yet fully understood, it is believed that these drugs help protect the cardiovascular system through several potential pathways. They may improve blood vessel function, reduce inflammation, and have positive effects on blood pressure and lipid profiles.

The cardiovascular benefits of semaglutide are significant because individuals with type 2 diabetes are at an elevated risk of heart disease. By incorporating semaglutide into their treatment plan, patients may not only achieve better blood sugar control and weight management but also contribute to the overall protection of their heart and blood vessels. This dual action makes semaglutide a valuable option for individuals seeking to manage their diabetes and reduce their cardiovascular risk. However, it is important for individuals to consult with their healthcare providers to determine the most suitable treatment plan and medications for their specific needs.

Risk Factors:

Although risk factors associated with semaglutides are

Nausea
Vomiting
Stomach Pain
Fatigue
Low Blood Sugar
Pancreatitis
Gall Bladder Disease
Kidney Damage
Allergic Reactions
Thyroid Tumors
Dysuria
Polyuria
Dizziness
Blurred Vision

Cosultation is necessary if these risk factors become a medical emergency.

Precautions:

Semaglutide pills may lead to thyroid tumor. So if you have any trouble in breathing or swallowing or if you feel any lump or swelling in neck region or face any voice changes then quick consultation is must. If semaglutide pills trigger an allergic reaction, notify your doctor. Patients with conditions like diabetic retinopathy, kidney disorders, gastroparesis, pancreatitis, intestinal disorders, or gall bladder disease may require special care. While semaglutide is not sedative but strenuous exercise combined with this medication can lead to excessively low blood sugar due to sweating, resulting in drowsiness, dizziness, and lethargy. Therefore, activities requiring full attention, like driving, should be avoided. Alcohol consumption while using this medication carries the risk of lowering blood sugar levels below normal.

For those planning to get pregnant, already pregnant, or suspecting pregnancy, consulting a doctor is necessary, as there may be potential risks related to pregnancy. Consultation with a doctor should occur two months before attempting pregnancy because medication adjustments may be needed.

Breastfeeding mothers should also consult with their doctors regarding the use of this medication.

Contraindications:

Semaglutide pills are not recommended for individuals with a personal or family history of thyroid tumors, specifically thyroid C cell tumors or medullary thyroid carcinoma (MTC). It is also contraindicated in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).